Dr. Jerry Vockley, MD, PhD | Member of ...

Dr. Gerard Vockley, MD, PhD

Claim this profile

UPMC Children's Hospital of Pittsburgh

Studies Phenylketonuria
Studies Lipid disorders
14 reported clinical trials
17 drugs studied

Affiliated Hospitals

Image of trial facility.
UPMC Children's Hospital Of Pittsburgh
Image of trial facility.
University Of Pittsburgh Medical Center - Children's Hospital Of Pittsburgh

Clinical Trials Gerard Vockley, MD, PhD is currently running

Image of trial facility.

ELAPRASE + Prophylactic Therapy

for Hunter Syndrome

The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome. In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR. Participants will be treated with ELAPRASE for up to 104 weeks. The prophylactic ITR will start 1 day prior to the start of ELAPRASE. The prophylactic ITR will consist of a 5-week cycle of: Rituximab (intravenously \[IV\], weekly for 4 weeks); Methotrexate (oral, 3 times per week for 5 weeks) and intravenous immunoglobulin (IVIG) (IV, every 4 weeks of the cycle). Following the completion of 1 cycle, an assessment will be made at Month 6, 12, and 18 regarding the need for administering another 5-week cycle of the ITR. Participants will be in the study for approximately 112 weeks (including 6 weeks for screening, up to 104 weeks for treatment, and 2 weeks for follow-up).
Recruiting3 awards Phase 48 criteria
Image of trial facility.

PTC923

for Phenylketonuria

This trial is testing the safety of a medication called PTC923 in people with phenylketonuria (PKU). PKU patients need to manage their blood phenylalanine levels carefully. PTC923 aims to help control these levels, making it easier for patients to manage their condition. PTC923 is a newer treatment for PKU, following earlier treatments like sapropterin and pegvaliase.
Recruiting2 awards Phase 34 criteria

More about Gerard Vockley, MD, PhD

Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Gerard Vockley, MD, PhD has experience with
  • Placebo
  • Neonate WGS Testing
  • Triheptanoin
  • Sodium Phenylbutyrate
  • None
  • HMI-103

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Gerard Vockley, MD, PhD specialize in?
Is Gerard Vockley, MD, PhD currently recruiting for clinical trials?
Are there any treatments that Gerard Vockley, MD, PhD has studied deeply?
What is the best way to schedule an appointment with Gerard Vockley, MD, PhD?
What is the office address of Gerard Vockley, MD, PhD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security